Amsterdam UMC Stichting

Running trials

• Not yet recruiting

  PANVIRAL: Safety, Feasibility and Immunogenicity of Intra-Tumoral ORCA-010 Oncolytic Virus Administration in Metastatic Pancreatic Cancer – A Single-Center Phase 1 Trial

  2026-527268-33-00· Phase 1· Source

• Not yet recruiting

  Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis

  NCT07441408· Phase 3· Source

• Not yet recruiting

  Safety and Efficacy of VX-828/Deutivacaftor Combination Therapy With and Without Tezacaftor in Subjects With Cystic Fibrosis

  2025-523400-72-00· Phase 2· Source

• Not yet recruiting

  A research study to evaluate how well etavopivat works in children with sickle cell disease

  2025-524464-38-00· Phase 3· Source

• Not yet recruiting

  A pivotal clinical study to investigate the safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis due to Metabolic dysfunction-associated steatohepatitis (MASH)

  2026-525755-82-00· Phase 3· Source

• Not yet recruiting

  A study to investigate safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis (stage F4 fibrosis) due to MASH (NEBULA-2)

  2026-525757-37-00· Phase 3· Source

• Not yet recruiting

  Addition of ritonavir to ibrutinib treatment in patients with chronic leukemia and certain types of lymphoma

  2026-526101-15-00· Phase 2· Source

• Not yet recruiting

  DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers

  NCT07707895· Phase 1/2· Source

• Recruiting

  A clinical trial to assess the efficacy and safety of ontunisertib compared to placebo in patients with fibrostenosing Crohn’s disease

  2026-525197-19-00· Phase 2· Source

• Recruiting

  Phase 3 Study of Investigator Choice of Chemotherapy with or without Zoldonrasib as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma

  2025-524928-21-00· Phase 3· Source

• Not yet recruiting

  Targeting fibrotic tissue with a radioactive-labelled Fibrobody, visible using a full-body PET/CT scan (FibroVision)

  2025-521143-20-00· Phase 1· Source

• Not yet recruiting

  Phase 3 Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC 6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma

  2025-524969-24-00· Phase 3· Source

• Not yet recruiting

  A Phase I Study using Oncolytic AdenoVirus Immunotherapy with Repeat Administrations in Recurrent GliOblastoma (VIRAGO)

  2025-524555-31-00· Phase 1· Source

• Recruiting

  Use of Indipamide to reduce progression of disability in people with primary and secondary progressive multiple sclerosis (MS).

  2026-525260-18-00· Phase 2· Source

• Recruiting

  Phase 3 Trial of Tarlatamab (SC vs IV) In Extensive-Stage Small Cell Lung Cancer After Platinum based First-line Chemotherapy (DeLLphi-315)

  2026-525489-23-00· Phase 3· Source

• Recruiting

  Research on two creams (Monobenzon / Imiquimod) together with the standard treatment for advanced or metastatic melanoma (ImMI).

  2024-520052-19-04· Phase 1/2· Source

• Not yet recruiting

  Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma With Pirtobrutinib in Combination With Epcoritamab if the Disease Comes Back After Previous Treatment.

  NCT07860775· Phase 2· Source

• Not yet recruiting

  A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies

  NCT07719348· Phase 1/2· Source

• Recruiting

  A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)

  2025-525009-18-00· Phase 3· Source

• Recruiting

  The RJVA-001 First in Human Trial in Adults with Inadequately Controlled Type 2 Diabetes.

  2025-524438-24-00· Phase 1/2· Source

• Recruiting

  A Phase IIb Study to Evaluate AZD8965 in Participants with Idiopathic Pulmonary Fibrosis (IPF)

  2025-525016-41-00· Phase 2· Source

• Recruiting

  A Study to Investigate Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Systemic Lupus Erythematosus

  NCT07630714· Phase 2· Source

• Recruiting

  Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer

  NCT07564141· Phase 3· Source

• Recruiting

  A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)

  NCT07636811· Phase 2· Source

• Recruiting

  Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment Regimens

  2025-524336-19-00· Phase 3· Source

• Recruiting

  Fibroblast markers to tackle fibrosis in immune-mediated inflammatory diseases

  2025-522834-30-01· Phase 2· Source

• Recruiting

  Methotrexate in paediatric and adolescent Crohn’s disease: an observational study

  2025-524129-42-00· Phase 4· Source

• Recruiting

  Post-INFECT: Investigating Neuroinflammation and its effects in post-COVID syndrome

  2025-522349-23-00· Phase 3· Source

• Recruiting

  Locating microclots with PET in post-COVID syndrome

  2025-522348-42-00· Phase 1/2· Source

• Not yet recruiting

  Comparing Intravenous or Intradermal Administration of Anti-CTLA-4 in Combination With Anti-PD1 Treatment in Patients With Melanoma

  NCT07615881· Phase 1/2· Source

• Recruiting

  PROTECx - Pembrolizumab Registry for Outcomes and Treatment Evaluation in Cervical Cancer

  2025-522883-34-00· Phase 4· Source

• Not yet recruiting

  PREOPANC-6 study: dendritic cell immunotherapy after FOLFIRINOX chemotherapy in patients with resectable pancreatic cancer

  2025-523134-28-00· Phase 2/3· Source

• Recruiting

  A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

  NCT07357727· Phase 3· Source

• Recruiting

  Study Investigating Tucatinib and Osimertinib Pharmacokinetics in Primary and Metastatic Brain Tumors: the STICK trial

  2025-522128-28-00· Phase 1· Source

• Recruiting

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07577856· Phase 3· Source

• Recruiting

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

  NCT07577843· Phase 3· Source

• Recruiting

  A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions

  NCT07422480· Phase 3· Source

• Recruiting

  A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)

  NCT07570173· Phase 2/3· Source

• Recruiting

  A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A

  NCT07416604· Phase 3· Source

• Recruiting

  Assessing Residual Inflammation and Macrophage Presence in Lupus Nephritis After 3 Months of Intensified Treatment With Prednisolone, Mycofenolate Mofetil and Voclosporin as Compared to Mycofenolate Mofetil and Prednisolone

  NCT07760480· Phase 4· Source

• Recruiting

  An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)

  NCT07365332· Phase 3· Source

• Recruiting

  A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis

  2025-521546-23-00· Phase 3· Source

• Recruiting

  Neoadjuvant gemcitabine and cisplatin in combination with perioperative pembrolizumab versus upfront surgery for patients with primary resectable and borderline resectable perihilar and distal cholangiocarcinoma (NEODISCO): A Multicentre Phase 2B/3 Randomised Controlled Trial

  2024-516898-72-00· Phase 2/3· Source

• Recruiting

  PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND IMMUNOGENICITY OF E-VIM VACCINE CVX1 WITH OR WITHOUT ICI IN THE TREATMENT OF SUBJECTS WITH MUSCLE INVASIVE BLADDER CANCER (MIBC) OR LOCALIZED OR LOCALLY ADVANCED RENAL CELL CANCER (RCC).

  2025-523781-25-00· Phase 1· Source

• Not yet recruiting

  Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy

  NCT07486687· Phase 3· Source

• Not yet recruiting

  Combining Latency Reversing Agents to Address the HIV Reservoir

  NCT07384624· Phase 1/2· Source

• Recruiting

  A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)

  NCT07463183· Phase 2· Source

• Recruiting

  A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

  NCT07351045· Phase 3· Source

• Recruiting

  A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

  NCT07361497· Phase 3· Source

• Recruiting

  Neoadjuvant FOLFOXIRI and Chemoradiotherapy versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy, followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer

  NCT07472868· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Pancreatic cancer13 recruiting
• Crohn's disease12 recruiting
• Multiple myeloma11 recruiting
• Lung cancer10 recruiting
• Colorectal cancer9 recruiting
• Gastric and esophageal cancer8 recruiting
• High blood pressure7 recruiting
• Acute myeloid leukemia5 recruiting
• Fatty liver disease (MASLD/MASH)5 recruiting
• Liver and biliary tract cancer5 recruiting
• Lupus (SLE)5 recruiting
• Pulmonary arterial hypertension5 recruiting
• Ulcerative colitis5 recruiting
• Bladder cancer4 recruiting
• Chronic lymphocytic leukaemia4 recruiting
• Idiopathic pulmonary fibrosis4 recruiting
• Melanoma4 recruiting
• Myelodysplastic syndromes4 recruiting
• Sickle cell disease4 recruiting
• Long COVID and ME/CFS3 recruiting
• Multiple sclerosis3 recruiting
• Ovarian cancer3 recruiting
• Rheumatoid arthritis3 recruiting
• Stroke3 recruiting
• Alzheimer disease2 recruiting
• Amyloidosis2 recruiting
• Ankylosing spondylitis2 recruiting
• Cervical cancer2 recruiting
• Childhood cancers2 recruiting
• Chronic kidney disease2 recruiting
• Chronic myeloid leukaemia2 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)2 recruiting
• Endometrial cancer2 recruiting
• Familial hypercholesterolaemia2 recruiting
• Follicular lymphoma2 recruiting
• Glioblastoma2 recruiting
• Head and neck cancer2 recruiting
• Heart failure2 recruiting
• HIV2 recruiting
• Metastatic breast cancer2 recruiting
• Myeloproliferative neoplasms2 recruiting
• Prostate cancer2 recruiting
• Type 2 diabetes2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Asthma1 recruiting
• Atrial fibrillation1 recruiting
• Cystic fibrosis1 recruiting
• Depression1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Frontotemporal dementia1 recruiting
• Gaucher disease1 recruiting
• Haemophilia1 recruiting
• Hodgkin lymphoma1 recruiting
• Mantle cell lymphoma1 recruiting
• Neuroendocrine tumours1 recruiting
• Obesity1 recruiting
• Psoriasis1 recruiting
• Sjögren's disease1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting
• Triple-negative breast cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

  NCT07221357· Phase 2/3· Source

• Completed

  Phase 2b Randomized, Double-Blind Study with Phage for CF Subjects with Pseudomonas Lung Infection

  2024-519856-94-00· Phase 2· Source

• Completed

  A Study With CIT-013 in RA Patients

  NCT06567470· Phase 2· Source

• Completed

  A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease

  NCT06926660· Phase 2· Source

• Recruiting

  Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis

  NCT06699849· Phase 2· Source

• Recruiting

  A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis

  NCT07012395· Phase 2· Source

• Completed

  A Study to see How Well and How Safely Different Treatments Work in a Group of Patients with Non-Small Cell Lung Cancer, Chosen Based on their Biomarker Status

  2024-511239-91-00· Phase 2· Source

• Active, not recruiting

  Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa

  NCT06716814· Phase 3· Source

• Recruiting

  3TR-PARTNER-RA

  2024-511470-79-00· Phase 4· Source

• Active, not recruiting

  A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis

  NCT06744920· Phase 3· Source

• Active, not recruiting

  Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

  NCT06608927· Phase 3· Source

• Active, not recruiting

  A trial to learn how safe AZD7798 is and how well it works in adults with ileal Crohn’s disease who have an ileostomy

  2024-514407-33-00· Phase 2· Source

• Completed

  Synaptic density and tau pathology in Alzheimer’s disease

  2024-517636-22-00· Phase 2· Source

• Completed

  DUET-study: A FEASIBILITY STUDY OF 177LU-PSMA RADIOLIGAND THERAPY ALTERNATED WITH RADIUM-223 IN PATIENTS WITH BONE-METASTATIC, OLIGO-METASTATIC HORMONE-SENSITIVE PROSTATE CANCER AFTER CURATIVE THERAPY.

  2024-518985-29-02· Phase 1/2· Source

• Completed

  PARADOX study

  2024-515278-28-00· Phase 4· Source

• Completed

  A Patient guided dose reduction strategy of tyrosine kinase inhibitors in chronic myeloid leukaemia: RODEO study

  2024-516511-24-00· Phase 4· Source

• Active, not recruiting

  A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer

  NCT06614192· Phase 2· Source

• Completed

  Precision psychiatry: Anti-inflammatory medication in Immuno-metabolic depression

  NCT05415397· Phase 3· Source

• Completed

  THE (COST)EFFECTIVENESS OF NEOADJUVANT FOLFIRINOX VERSUS NEOADJUVANT GEMCITABINE BASED CHEMORADIOTHERAPY AND ADJUVANT GEMCITABINE FOR (BORDERLINE) RESECTABLE PANCREATIC CANCER (PREOPANC-2 STUDY)

  2024-516260-29-00· Phase 3· Source

• Recruiting

  Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)

  NCT06274801· Phase 3· Source

• Active, not recruiting

  A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.

  NCT06517758· Phase 3· Source

• Completed

  Effects of maintenance cabozantinib+BSC versus BSC in children and AYA with osteosarcoma. ( CabOSTar )

  NCT06341712· Phase 2· Source

• Completed

  A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)

  NCT06333860· Phase 4· Source

• Completed

  A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD)

  NCT06309992· Phase 3· Source

• Active, not recruiting

  A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)

  NCT06282159· Phase 2· Source

• Active, not recruiting

  A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)

  NCT06140836· Phase 3· Source

• Active, not recruiting

  Galunisertib Combined With Capecitabine in Advanced CRC With PM

  NCT05700656· Phase 1/2· Source

• Completed

  DiEtary Sodium Intake Effects on Ertugliflozin-induced Changes in GFR, reNal Oxygenation and Systemic Hemodynamics: the DESIGN Study

  NCT05727579· Phase 4· Source

• Completed

  Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial – Follow Up Long Term Extension (IMPAHCT-FUL)

  NCT05557942· Phase 3· Source

• Completed

  A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Cardiomyopathy

  NCT05582395· Phase 3· Source

• Active, not recruiting

  A Study of Secukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remission

  NCT05622708· Phase 4· Source

• Completed

  A trial in patients with blood cancer and lymphatic system cancer looking at finding the optimal dose of BMF-219

  NCT05153330· Phase 1· Source

• Completed

  A Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (HeFH) Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1)

  NCT05694260· Phase 2· Source

• Active, not recruiting

  Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis

  NCT05588843· Phase 2· Source

• Active, not recruiting

  Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis

  NCT05556096· Phase 3· Source

• Recruiting

  A Clinical Imaging Study of the Changes in [18F]F-AraG Uptake Following Anti-PD-1 Therapy in Non-small Cell Lung Cancer

  NCT05701176· Phase 1/2· Source

• Active, not recruiting

  IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)

  NCT05155254· Phase 3· Source

• Recruiting

  InDuctIon TREatment with SubCuTaneous Infliximab for Crohn's Disease

  NCT06059989· Phase 3· Source

• Active, not recruiting

  A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

  NCT04961567· Phase 3· Source

• Completed

  A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer

  NCT04702880· Phase 2· Source

• Completed

  Lutetium-177-PSMA-617 in Oligo-metastatic Hormone Sensitive Prostate Cancer

  NCT04443062· Phase 2· Source

• Completed

  A randomized phase II study of second line treatment with liposomal irinotecan and S1 versus liposomal irinotecan and 5-fluorouracil in patients with metastatic pancreatic cancer who failed on first line gemcitabine-based chemotherapy

  2023-509463-24-01· Phase 2· Source

• Active, not recruiting

  Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

  NCT03937219· Phase 3· Source

• Completed

  Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

  NCT03872401· Phase 3· Source

• Completed

  Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma

  NCT03570892· Phase 3· Source

• Active, not recruiting

  Blinatumomab Added to Prephase and Consolidation Therapy in Precursor B-acute Lymphoblastic Leukemia in Adults.

  NCT03541083· Phase 2· Source

• Completed

  A prospective, multicenter, phase-II trial of ibrutinib plus venetoclax in physically fit patients with creatinine clearance ≥ 30 ml/min who have relapsed or refractory chronic lymphocytic leukemia (RR-CLL) with or without TP53 aberrations, HOVON 141 CLL / VIsion Trial of the HOVON and Nordic CLL study groups

  NCT03226301· Phase 2· Source

• Completed

  Sustained treatment-free period in the course of a disease when symptoms become less severe in BCR-ABL+ chronic myeloid leukemia: a prospective study comparing a drug called Nilotinib versus another called Imatinib with switch to Nilotinib in absence of optimal response.

  NCT02602314· Phase 4· Source

• Completed

  autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized European MCL Network trial

  2024-511235-10-00· Phase 3· Source

• Completed

  HD21

  NCT02661503· Phase 3· Source